Little Known Company Behind Promising Cure to Alzheimer’s is Undervalued ($SAVA)
Updated: Dec 29, 2021
I found this wonderful article on SAVA by James Cannon:
"Cassava is developing an Alzheimer’s drug Simufilam that is currently in Phase 3 (the final phase). It is an oral medication taken twice daily, and in the Phase 2 trial, is the only drug to actually improve cognition in Alzheimer’s patients. It doesn’t just slow down the disease, but reverse it! And it’s extremely safe. Such results are unheard of in the history of Alzheimer’s treatments."